We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-43.14%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$100M
AUM Growth
-$36.6M
(-27%)
Cap. Flow
-$10.6M
Cap. Flow
% of AUM
-10.62%
Top 10 Holdings %
Top 10 Hldgs %
93.38%
Holding
105
New
21
Increased
12
Reduced
17
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
reAlpha
AIRE
|
+$3.43M |
| 2 |
FMTO
Femto Technologies Inc. Common Stock
FMTO
|
+$2.56M |
| 3 |
GGE
Green Giant Inc. Common Stock
GGE
|
+$2.37M |
| 4 |
MMAT
Meta Materials Inc. Common Stock
MMAT
|
+$1.64M |
| 5 |
Phunware
PHUN
|
+$1.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$12.9M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.67M |
| 3 |
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
|
+$2.17M |
| 4 |
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
|
+$817K |
| 5 |
AIOS
AIOS Tech
AIOS
|
+$528K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 4.2% |
| 2 | Healthcare | 3.82% |
| 3 | Energy | 0.81% |
| 4 | Real Estate | 0.76% |
| 5 | Materials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $45.3M | 45.34% |
954
-66
| -6% | -$29.4K |
|
2
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $41.7M | 41.68% |
2,077
-1,232
| -37% | -$259K |
|
3
Tonix Pharmaceuticals
TNXP
$158M
| $1.25M | 1.25% |
967
+577
| +148% | +$929K |
|
|
FMTO
4
DELISTED
Femto Technologies Inc. Common Stock
FMTO
| $1.05M | 1.05% |
+2
| New | +$2.56M |
|
|
MMAT
5
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $904K | 0.9% |
+137,021
| New | +$1.64M |
|
|
6
Phunware
PHUN
$43.8M
| $821K | 0.82% |
+200,132
| New | +$1.41M |
|
7
Recon Technology
RCON
$39.6M
| $805K | 0.81% |
191,647
+26,910
| +16% | +$133K |
|
8
PUT
Bit Digital
BTBT
$459M
| $514K | 0.51% |
1,214
+170
| +16% | +$444 |
|
|
AKTX
9
Akari Therapeutics
AKTX
$14.8M
| $512K | 0.51% |
4,101
-351
| -8% | -$46.4K |
|
10
Cyngn
CYN
$15.7M
| $507K | 0.51% |
+234
| New | +$952K |
|
11
Treasure Global
TGL
$6.2M
| $426K | 0.43% |
+68
| New | +$1.11M |
|
12
Gevo
GEVO
$363M
| $421K | 0.42% |
+363,029
| New | +$414K |
|
|
DUO
13
Fangdd Network Group
DUO
$23.4M
| $392K | 0.39% |
36,375
-2,485
| -6% | -$31.1K |
|
|
14
reAlpha
AIRE
$7.56M
| $370K | 0.37% |
+7,430
| New | +$3.43M |
|
|
TC
15
TuanChe
TC
$61M
| $347K | 0.35% |
5,689
-410
| -7% | -$43.2K |
|
16
PUT
Globus Maritime Ltd
GLBS
$60.9M
| $316K | 0.32% |
+1,192
| New | +$2.55K |
|
17
Ascent Solar Technologies
ASTI
$28.9M
| $313K | 0.31% |
+3,594
| New | +$354K |
|
18
Arcadia Biosciences
RKDA
$1.37M
| $305K | 0.3% |
97,305
+64,600
| +198% | +$202K |
|
|
LIPO
19
DELISTED
Lipella Pharmaceuticals
LIPO
| $275K | 0.28% |
+33,729
| New | +$314K |
|
20
iBio
IBIO
$69.1M
| $242K | 0.24% |
+176,748
| New | +$772K |
|
|
CKPT
21
PUT
DELISTED
Checkpoint Therapeutics
CKPT
| $218K | 0.22% |
+952
| New | +$2.07K |
|
22
InMed Pharmaceuticals
INM
$8.92M
| $213K | 0.21% |
+25,597
| New | +$248K |
|
23
Revelation Biosciences
REVB
$4.06M
| $202K | 0.2% |
70
| – | – |
|
|
BCTX
24
PUT
Briacell Therapeutics
BCTX
$30.2M
| $197K | 0.2% |
+2
| New | +$1.44K |
|
|
25
CALL
Gevo
GEVO
$363M
| $194K | 0.19% |
1,675
+478
| +40% | +$546 |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q4 2023 Portfolio in Review
As of Q4 2023, Sabby Management held 105 positions worth $100M, down 27% from $137M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Sabby Management withdrew a net $10.6M in Q4 2023, closing 48 positions and reducing 17 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $12.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 4.2% of assets, up from 0.43% a quarter earlier, followed by Healthcare and Energy.
Against the trend, Sabby Management opened a new position in reAlpha worth $370K.
- Sabby Management's largest Q4 2023 buy was reAlpha: 7,430 shares worth $370K.
- Sabby Management added most to Tonix Pharmaceuticals in Q4 2023, an estimated $929K increase.
- Sabby Management's biggest Q4 2023 reduction was GlucoTrack, cutting an estimated $349K.
- Sabby Management fully exited iShares Russell 2000 ETF in Q4 2023, selling an estimated $12.9M.
- Sabby Management's ten largest holdings make up 93% of its $100M portfolio in Q4 2023.
- Sabby Management opened 21 new positions and closed 48 in Q4 2023.
- Sabby Management's portfolio value fell 27% quarter-over-quarter to $100M.
Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.